• A small number of patients may have stubborn rings that require more aggressive endoscopic or surgical intervention. (medscape.com)
  • Distribution of the patients with foreign body ingestion, according to the object ingested and the endoscopic finding. (revistagastroenterologiamexico.org)
  • The aim of the present study was to describe the clinical, radiographic, and endoscopic characteristics of patients with FB ingestion, as well as the factors associated with the anatomic location and the type of object ingested. (revistagastroenterologiamexico.org)
  • During regular endoscopic follow-up, multilevel circumferential biopsies should document the evolution of the histologic changes in the lower esophagus and at the gastroesophageal junction of these patients. (pharmaceuticalintelligence.com)
  • Additionally, in patients undergoing interventions for achalasia (eg, surgery, peroral endoscopic myotomy), measurement of esophagogastric junction distensibility during and after the intervention accurately measures clinical response to interventions and can help guide therapy. (msdmanuals.com)
  • Esophagogastric junction outflow obstruction (EGJOO) is a condition characterized by HRM findings of impaired EGJ function but, at least in part, preserved peristalsis. (abdominalkey.com)
  • Approximately one-third of patients with gastric cancer undergoes an avoidable lymph node dissection. (frontiersin.org)
  • Compliance with NCCN Guidelines and stage-specific therapy at presentation for the treatment of patients with gastric cancer was poor, which was a significant finding given that compliant care was associated with a 55% reduction in the hazard of death. (jnccn.org)
  • A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. (helsedirektoratet.no)
  • At the time of diagnosis of gastric cancer approximately one third of patients already have metastases. (unige.ch)
  • Gulam A. Manji, MD, PhD, of Columbia University Medical Center, discusses phase II results on perioperative combination chemotherapy and pembrolizumab in patients with resectable gastric cancer. (ascopost.com)
  • Background Metastatic gastric cancer and cancer of the esophagogastric junction (GC/EGJ) is an aggressive disease with poor prognosis. (gencat.cat)
  • The latter procedure, along with peritoneal lavage is recommended for stage IB-III patients before surgical resection ( 9 ). (frontiersin.org)
  • This case describes a patient who had undergone a left hepatic resection with mesh pledgets sutured along the cut edge of the liver. (hindawi.com)
  • The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. (helsedirektoratet.no)
  • Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. (helsedirektoratet.no)
  • Can multimodal treatment with tumor resection and metastasectomy combined with perioperative chemotherapy, increase the chances of survival in oligometastatic patients? (unige.ch)
  • The Dutch D1/D2 trial reported an increased median survival for a subgroup of patients with single metastasis who underwent resection. (unige.ch)
  • Multimodal treatment with resection doubled the median survival of oligometastatic patients in the German AIO-FLOT 3 study and as a consequence, the AIO-FLOT 5 (RENAISSANCE) trial was designed. (unige.ch)
  • Patients with oligometastatic gastric and esophagogastric junction cancer are randomized after chemotherapy to either undergo resection followed by adjuvant chemotherapy or to undergo definitive chemotherapy. (unige.ch)
  • The results of the ongoing randomized trials will show if oligometastatic patients benefit from a multimodal treatment with resection. (unige.ch)
  • This international, multicenter, randomized, double-blind phase III study intends to recruit 680 patients who have received radical gastrectomy (R0 resection, D2 or more extended lymphadenectomy) with postoperative pathological stage II or III (AJCC Cancer Staging Manual, 8th Edition) gastric or EGJ adenocarcinoma to evaluate the efficacy and safety of JS001 combined with postoperative adjuvant chemotherapy versus placebo combined with postoperative adjuvant chemotherapy. (centerwatch.com)
  • Primary DCF therapy for patients with unresectable esophageal cancer resulted in conversion surgery for 41.7% (20/48) of patients, in which R0 resection was achieved in 19 patients (39.6%) [ 5 ]. (biomedcentral.com)
  • Can Some Patients With Esophageal Cancer Avoid Surgery? (medscape.com)
  • MADRID - More than one third of patients with locally advanced esophageal cancer who have a complete clinical response to neoadjuvant chemoradiotherapy may be able to safely avoid major surgery, findings from the Dutch SANO-trial suggest. (medscape.com)
  • To compare active surveillance with standard surgery, the team conducted a phase 3 noninferiority stepped-wedge cluster randomized trial involving patients with locally advanced esophageal cancer. (medscape.com)
  • A study by Fogh et al of induction chemoradiotherapy followed by surgery, a strategy that is widely used in treating esophageal cancer, found that perioperative morbidity and mortality with this approach was not significantly different in patients aged 70 years or older compared with younger patients. (medscape.com)
  • Additionally, patients with TNM-staged cancer were more likely to receive compliant care, perhaps a result of having received more intensive therapy. (jnccn.org)
  • Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. (jnccn.org)
  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. (helsedirektoratet.no)
  • Background/Aim: Impact of second-line chemotherapy in unresectable advanced/recurrent gastric/esophagogastric junction cancer (AGC) remains unclear. (iiarjournals.org)
  • Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO. (springermedizin.at)
  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet 376: 687-697, 2010. (springermedizin.at)
  • Multicenter phase 2: Capecitabine (CAP) + oxaliplatin (OX) + bevacizumab (BEV) + trastuzumab (TRAS) for patients (pts) with metastatic esophagogastric cancer (MEGCA). (springermedizin.at)
  • We evaluated the clinical impact of the preoperative platelet-to-lymphocyte ratio (PLR) in patients with resectable esophageal cancer who received curative treatment. (iiarjournals.org)
  • Patients and Methods: This study included 168 patients who underwent curative surgery followed by perioperative adjuvant chemotherapy for esophageal cancer between 2005 and 2018. (iiarjournals.org)
  • Conclusion: The PLR had a clinical impact on the long-term oncological outcomes of patients with esophageal cancer treated with curative intent. (iiarjournals.org)
  • Therefore, the PLR might be a promising prognostic factor for patients with esophageal cancer. (iiarjournals.org)
  • The aim of this study was to evaluate the relationship between the monocyte count assessed at diagnosis and disease-free survival and prognosis in patients with esophageal cancer. (researchsquare.com)
  • The retrospective study included 145 patients with esophageal cancer who presented to Van Training and Research Hospital Medical Oncology outpatient clinic between January 2015 and September 2020. (researchsquare.com)
  • Our findings showed that monocyte count is a prognostic factor affecting disease-free survival in patients with esophageal cancer, regardless of histological subtype. (researchsquare.com)
  • Given that the monocyte count at the time of diagnosis dynamically reflects the systemic inflammatory response to cancer, studies often measure monocyte count at the time of diagnosis in their patients. (researchsquare.com)
  • In the present study, we aimed to investigate whether the monocyte count measured at the time of diagnosis can be used as a new prognostic biomarker in predicting disease-free survival in patients with esophageal cancer. (researchsquare.com)
  • Delays in surgery for esophageal cancer did not appear to have much impact on patients' relative survival for early-stage cancer compared with patients who had surgery early, but they did reduce the relative survival rate by almost half for patients with more advanced disease, according to an. (ascopost.com)
  • Using whole-genome sequencing to contrast genomic alterations in patients with stable Barrett's esophagus compared to patients whose Barrett's progressed to esophageal adenocarcinoma, Paulson et al reported that DNA changes presaging esophageal cancer can be spotted years before cancer develops. (ascopost.com)
  • Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. (springer.com)
  • Characteristics and correlates of increasing use of surgery in Taiwanese cancer patients' last month of life, 2001-2010. (springer.com)
  • Eligible patients diagnosed between 2008 and 2013 were identified in the Taiwan Cancer Registry. (oncotarget.com)
  • The results demonstrate that primary bDCF therapy for high-risk patients with advanced esophageal cancer is feasible and safe in both chemotherapeutic and perioperative periods without a reduction in the efficacy of DCF therapy. (biomedcentral.com)
  • Therefore, myelosuppression and gastrointestinal side effects caused by preoperative DCF therapy may worsen postoperative infections leading to life-threatening diseases in high-risk patients with esophageal cancer and may reduce long-term survival benefits by increasing the incidence of postoperative infections. (biomedcentral.com)
  • BACKGROUND: The optimal postoperative surveillance protocol after esophagectomy for patients with esophageal cancer has still not been established. (bvsalud.org)
  • STUDY DESIGN: We enrolled 416 patients with esophageal and esophagogastric junctional cancer who had undergone thoracoscopic esophagectomy at Tokai University Hospital. (bvsalud.org)
  • Incidence rates for esophagogastric junction cancer are rising rapidly worldwide possibly due to the economic development and demographic changes. (bvsalud.org)
  • Therefore, increased attention has been paid to the prevention, diagnosis, and the treatment of esophagogastric junction cancer. (bvsalud.org)
  • Although there are discrepancies in the treatment strategy between Asian and Western countries, surgery remains the mainstay of treatment for esophagogastric junction cancer. (bvsalud.org)
  • In this review, we will focus on the treatment of locally advanced resectable esophagogastric junction cancer, and discuss the current status and future perspectives of the perioperative treatment including chemotherapy, radiation therapy, and immunotherapy, as well as the surgical strategy. (bvsalud.org)
  • Better understanding of the latest treatment strategy and future overlook may enable to standardize and individualize the treatment for esophagogastric junction cancer, thus leading to better prognosis for those patients. (bvsalud.org)
  • Because esophageal cancer is increasing in the Western world there is an urgent need for substantial improvements in the early diagnosis, treatment and continued management of these patients. (amegroups.com)
  • It is disturbing to note that over the last sixty years treatments have changed for esophageal cancer, but unfortunately the patient outcomes remain abysmal with 85% to 90% of patients dying within five years. (amegroups.com)
  • It is imperative that cancer organizations and funding agencies provide funding and resources that will in turn lead to cutting- edge developments in understanding esophageal cancer and decrease the incidence and improve the survival for patients with esophageal cancer. (amegroups.com)
  • Esophageal and esophagogastric junction cancer. (epnet.com)
  • Available at: https://www.cancer.gov/types/esophageal/patient/esophageal-treatment-pdq#section/_159. (epnet.com)
  • Being familiar with the current management of breast cancer will help clinicians support their patients and to communicate with specialists in the multidisciplinary team. (nccn.org)
  • CADTH recommends that Keytruda should be reimbursed by public drug plans for the treatment of esophageal or human epidermal growth factor receptor 2 (HER2)-negative esophagogastric junction (EGJ) cancer that cannot be removed by surgery or is metastatic, if certain conditions are met. (canjhealthtechnol.ca)
  • Keytruda should only be covered to treat adult patients who have not received previous treatment for advanced or metastatic esophageal or EGJ cancer and who have good performance status. (canjhealthtechnol.ca)
  • Approximately 5% of patients diagnosed with advanced esophageal cancer are expected to be alive in 5 years. (canjhealthtechnol.ca)
  • Still, with the notion that adenocarcinoma of the esophagus is an aggressive cancer once documented, important questions still are in need of answers for patients suffering from reflux symptoms. (pharmaceuticalintelligence.com)
  • A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. (cdc.gov)
  • Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. (cdc.gov)
  • Data for patients included in the SCP for OG cancer at SUS Lund from 2015 to 2019 were collected from medical records. (cancercentrum.se)
  • I beskrivningen av förloppet står det att bland annat symtom som nytillkomna sväljsvårigheter ska väcka misstanke om cancer och då ska en snabb remiss skickas för gastroskopi (undersökning där en slang med kamera förs ner i magsäcken). (cancercentrum.se)
  • SVF startas då en välgrundad misstanke (VGM) uppstår, vilket innebär att det föreligger en betydande risk för cancer. (cancercentrum.se)
  • Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. (helsedirektoratet.no)
  • Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. (helsedirektoratet.no)
  • Schatzki ring is a benign, thin, circular mucosal and submucosal membrane seen at the squamocolumnar junction of the distal esophagus that does not contain muscularis propria. (medscape.com)
  • Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). (jnccn.org)
  • This procedure is performed on patients with GERD, and it helps prevent acid from coming back up the esophagus. (careerstep.com)
  • Adenocarcinoma of the gastroesophageal junction (GEJ or GE junction, a specific part of the esophagus where the esophagus and stomach meet) is a specific subset of esophagus cancers . (medicinenet.com)
  • Adenocarcinoma of the GE junction describes cancers that arise either in the lower esophagus or upper stomach, very close to the GE junction. (medicinenet.com)
  • Evidence from 1 phase III, randomized, double-blind, placebo-controlled trial demonstrated that treatment with pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) resulted in added survival benefit when used for the first-line treatment of patients with locally advanced unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced or metastatic Siewert type I adenocarcinoma of the EGJ. (canjhealthtechnol.ca)
  • despite their increased risk of tumor formation, most patients who have Barrett's esophagus die of other causes. (pharmaceuticalintelligence.com)
  • Patients with GERD may also experience significant complications associated with the disease, such as esophagitis, stricture, and Barrett esophagus. (medscape.com)
  • Zev Wainberg, MD, of the University of California, Los Angeles Medical Center, discusses preliminary data on the safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with budigalimab and FOLFOX for the first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. (ascopost.com)
  • Clinicians need to know the nuances of using neoadjuvant and adjuvant targeted therapy and immunotherapy to improve outcomes for their patients with resected early-stage and locally advanced NSCLC. (nccn.org)
  • Rather, manometry may be considered in patients who do not respond to empiric medical treatment and have normal findings on endoscopy. (medscape.com)
  • It remains unclear if patients experiencing reflux symptoms should undergo mandatory endoscopy with biopsies at the esophagogastric junction. (pharmaceuticalintelligence.com)
  • Giannini EG, Zentilin P, Dulbecco P, Vigneri S, Scarlata P, Savarino V. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. (medscape.com)
  • After 2 years, researchers found no significant differences in overall and disease-free survival between patients on active surveillance and those who received surgery either immediately following neoadjuvant chemoradiotherapy or who switched from active surveillance to surgery. (medscape.com)
  • Overall, patients who underwent active surveillance had "noninferior overall survival at 2 years," said Berend J. Van der Wilk, PhD candidate, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands, who presented the findings at the European Society for Medical Oncology (ESMO) Annual Meeting 2023 on October 20. (medscape.com)
  • The potential pitfalls of an active surveillance approach is that patients may develop unresectable tumor regrowths, "possibly resulting in inferior overall survival. (medscape.com)
  • 001). TNM-staged patients receiving compliant care had a median survival of 25.3 months compared with 15.1 months for compliant SS patients. (jnccn.org)
  • Combined with the improved survival among compliant TNM-staged patients, these differences have meaningful implications for health services research. (jnccn.org)
  • Here, we show that MUC16 expression is associated with disease progression, basal-like and squamous tumor subtypes, increased tumor metastasis, and short-term survival of PDAC patients. (unc.edu)
  • This retrospective analysis aimed to identify factors affecting prognosis in chemotherapy for patients with AGC, including the importance of progression-free survival in second-line chemotherapy (PFS-2). (iiarjournals.org)
  • The effect of post-Cx% on survival outcomes adjusted for the types of chemotherapy and patient characteristics was evaluated by meta-regression. (deepdyve.com)
  • Although the survival rate after curative treatment gradually improves, more than half of patients develop recurrent disease, even after curative treatment, and the prognosis of patients with recurrence is poor ( 5 , 6 ). (iiarjournals.org)
  • Therefore, if physicians manage and control perioperative systemic inflammation using optimal screening tools, they may be able to improve patient survival. (iiarjournals.org)
  • Disease-free survival was 17.3 months (95% CI: 8.4-26.2) in patients with a monocyte count ≥515/μL as opposed to 38.5 months (95% CI: 28. (researchsquare.com)
  • In the phase III RATIONALE-302 trial reported in the Journal of Clinical Oncology, Shen et al found that the anti-PD-1 antibody tislelizumab significantly improved overall survival vs chemotherapy in the second-line treatment of patients with advanced or metastatic esophageal squamous cell. (ascopost.com)
  • After matching, patients who underwent UE for clinical stage II ESCC had median survival/3-year overall survival (OS) rates of 27.8 months/39.2% compared with 32.7 months/49.8% in the NCRT group ( p = 0.508). (springer.com)
  • A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. (springer.com)
  • The current results provide the first clinical evidence that CCRT coupled with IGRT is associated with better overall survival when compared with CCRT without IGRT in NOL-ESCC patients. (oncotarget.com)
  • In the TAGS study, trifluridine/tipiracil (FTD/TPI) improved overall survival (OS) compared with placebo in heavily pre-treated patients. (gencat.cat)
  • Conclusions This analysis confirms the efficacy and safety of FTD/TPI in patients with GC/EGJ in third and later lines with a survival benefit that seems slightly superior in 3L treatment. (gencat.cat)
  • With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients. (e-cancer.fr)
  • Even in patients who do respond, the duration of response is often short, and their survival is quite limited. (canjhealthtechnol.ca)
  • The diagnosis of achalasia and EGJOO is suspected in patients who have long-standing dysphagia to solids and liquids with regurgitation of undigested material that can include saliva. (abdominalkey.com)
  • Occult malignant infiltration of the gastroesophageal junction is a rare but important differential diagnosis that affects about 2% of patients evaluated for achalasia. (abdominalkey.com)
  • This technique can be used to evaluate achalasia and can provide useful diagnostic information where high-resolution manometry is nondiagnostic or if the patient cannot tolerate manometry. (msdmanuals.com)
  • Liquid biopsy: The genomic alterations of solid cancers can be identified by evaluating circulating tumor DNA (ctDNA) in the blood This procedure is used more in patients who cannot undergo traditional biopsy, but can also be performed in other patients to gather more evidence for management. (medscape.com)
  • Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. (jnccn.org)
  • We suggest that an international collaborative study using the same definition of EGJ adenocarcinoma may be helpful not only for clarifying the characteristics of these cancers but also for improving the clinical outcome of these patients. (elsevierpure.com)
  • recurrence occurred within 24 months in 112 patients (88%), and 51 of these patients (40%) developed some new symptom(s) (symptomatic group) before the diagnosis of recurrence. (bvsalud.org)
  • The number of patients who developed recurrence within 6 months was significantly higher in the symptomatic group compared with that in the asymptomatic group (66.7% vs 46.0%, p = 0.02). (bvsalud.org)
  • Patients who have reflux disease are not necessarily symptomatic. (pharmaceuticalintelligence.com)
  • Lymph node metastasis is an important clinical issue in AEG patients. (biomedcentral.com)
  • Van der Wilk said those strong outcomes create some uncertainty as to whether all patients need standard surgery after chemoradiotherapy. (medscape.com)
  • Background In people with lower-extremity peripheral artery disease, the effects of exercise on patient-reported outcomes remain unclear. (unc.edu)
  • Background: Perioperative systemic inflammation affects the long-term oncological outcomes of patients with malignancies. (iiarjournals.org)
  • The outcomes of patients receiving "NCRT followed by surgery" or "UE" strategies were compared. (springer.com)
  • Image-guided radiotherapy (IGRT) is an advanced radiotherapy technology with great potential to improve patient outcomes via improved radiotherapy delivery [ 7 ]. (oncotarget.com)
  • In order to optimize overall patient outcomes, clinicians need to understand the evidence behind the current guidelines' recommendations, the rationale for appropriate treatment selection, and the management of any treatment- or multiple myeloma-specific adverse events. (nccn.org)
  • Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. (cdc.gov)
  • The study compared the perioperative morbidity and mortality of patients aged 70 years or older with those of patients younger than 70 years who underwent chemoradiotherapy followed by esophagectomy. (medscape.com)
  • Before surgical intervention, patients must undergo anatomic or physiogic testing to confirm that there is objective evidence of gastroesophageal reflux disease (GERD). (medscape.com)
  • JS001/placebo will be given for up to 17 cycles after surgery, until intolerable toxicity, disease recurrence, patient's withdrawal of consent, investigator's judgment that the patient needs to be withdrawn from the study treatment, or death, whichever comes first. (centerwatch.com)
  • Clinicians are challenged to remain up-to-date about the treatment advances that will enable them to make informed decisions to optimize the clinical outcome of patients with relapsed/refractory disease. (nccn.org)
  • Input from patient groups indicated that patients desire new effective therapies that prolong OS, improve quality of life (QoL), reduce disease symptoms, and have tolerable side effects. (canjhealthtechnol.ca)
  • Accumulating evidence shows that in addition to the characteristics of the tumor, the immune response of the patient is also highly important for determining the prognosis. (researchsquare.com)
  • All patients undergoing laparoscopic repair of primary or recurrent large hiatal hernia, and with intraoperative finding of weak diaphragmatic pillars, as judged by the surgeon, were included, from June 2004 to July 2005, in a prospective observational study. (unisr.it)
  • Six patients (4 for primary and 2 for recurrent hernia) received biomesh hiatoplasty. (unisr.it)
  • On one hand, insufficient lymphadenectomy may result in understaging and undertreatment of a patient, on the other hand, unnecessary lymph node dissection may result in a higher rate of postoperative complications. (frontiersin.org)
  • Seat the patient upright on a treatment couch across from the endoscopist. (medscape.com)
  • Patients and Methods: Data from a total of 109 patients with AGC that received second-line treatment were analyzed with the aim of clarifying prognostic factors. (iiarjournals.org)
  • Therefore, it is necessary to determine prognostic factors and to establish which patients with prognostic factors require more aggressive treatment. (iiarjournals.org)
  • Of course, even if Merck can win an FDA approval based on these latest data, patients won't be eligible for Keytruda until they have already failed on another treatment. (e-cancer.fr)
  • Adjuvant treatment options for patients with advanced renal cell carcinoma (RCC) following surgery are continually evolving, and new treatment options for different stages of RCC are being approved. (nccn.org)
  • Many patients do not respond to available treatment options. (canjhealthtechnol.ca)
  • Given all the evidence, pERC concluded that pembrolizumab plus cisplatin and 5-FU met some of the needs identified by patients because it provides an additional treatment option with improved OS and a manageable safety profile. (canjhealthtechnol.ca)
  • A total of 584 patients were included, of whom 347 started treatment. (cancercentrum.se)
  • The low proportions of patients starting treatment within the target times indicates a great need for improvement. (cancercentrum.se)
  • NGS: When limited tissue is available for testing or if the patient cannot undergo traditional biopsy, the use of limited molecular diagnostic panels may quickly exhaust the sample. (medscape.com)
  • Methods - Four patients presented with clinical and radiological evidence of a leak post LSG. (sages.org)
  • thus, a thorough preoperative evaluation is needed for appropriate patient selection to ensure the best clinical outcome. (medscape.com)
  • In other words, Van der Wilk asked, "Should we be willing to follow an active surveillance, organ-sparing strategy for patients with a clinical response? (medscape.com)
  • More than 300 patients who achieved a complete clinical response 12 weeks after completing chemoradiotherapy were randomly assigned to undergo standard surgery or active surveillance. (medscape.com)
  • As reported in the Journal of Clinical Oncology by Maron et al, a retrospective study found that use of EGFR inhibitor therapy was associated with benefit in patients with unresectable or metastatic EGFR-amplified gastroesophageal adenocarcinoma. (ascopost.com)
  • Data from 2503 patients with clinical stages II and III ESCC diagnosed between 2008 and 2014 were obtained from a nationwide database. (springer.com)
  • Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma. (springer.com)
  • Although concurrent chemoradiotherapy (CCRT) coupled with image-guided radiotherapy (IGRT) is associated with a theoretical benefit in non-operated localized esophageal squamous cell carcinoma (NOL-ESCC) patients, there is currently no clinical evidence to support this. (oncotarget.com)
  • METHODS: Overall, 91 patients who underwent thoracoscopic esophagectomy with cervical esophago-gastric anastomosis were included. (bvsalud.org)
  • Patients and methods Patients were divided into a 3L group (126 and 64 in FTD/TPI and placebo arms, respectively) and 4L+ group (211 and 106 in FTD/TPI and placebo arms, respectively). (gencat.cat)
  • Patients on active surveillance who experienced locoregional regrowth could still undergo surgery, Van der Wilk said. (medscape.com)
  • This study investigated the feasibility and outcome of an esophagectomy after bDCF therapy for patients with advanced esophageal squamous cell carcinoma. (biomedcentral.com)
  • Fifty-nine patients with esophageal carcinoma underwent an esophagectomy after DCF or bDCF therapy as primary chemotherapy. (biomedcentral.com)
  • OAGB, as all Omega-loop surgical strategies, is characterized by the direct anastomosis of the biliopancreatic loop to the stomach, instead of interposing an alimentary loop as in the Roux-en-Y procedures. (nature.com)
  • Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. (helsedirektoratet.no)
  • Since the 1950s, several investigators have published reports of patients with dysphagia who had associated lower esophageal ringlike constrictions, but each investigator had a different opinion as to the cause and nature of these rings. (medscape.com)
  • The pathogenesis is not clear, and patients typically present with intermittent nonprogressive dysphagia for solids. (medscape.com)
  • Dysphagia predictably occurs in patients with a luminal diameter less than 13 mm and may vary between 13-20 mm, depending on the size and type of bolus. (medscape.com)
  • however, few of these patients exhibit any symptoms of dysphagia. (medscape.com)
  • The feasibility of DCF therapy is a concern, particularly for elderly patients, patients with moderate organ disorders, and patients suffering from malnutrition caused by dysphagia or insufficient oral intake. (biomedcentral.com)
  • Dysphagia occurs in approximately one third of patients. (medscape.com)
  • Patients with dysphagia experience a sensation that food is stuck, particularly in the retrosternal area. (medscape.com)
  • However, a diagnosis of GERD based on the presence of typical symptoms is correct in only 70% of patients. (medscape.com)
  • According to the guidelines, for patients with symptoms and history consistent with uncomplicated GERD, the diagnosis of GERD may be assumed and empirical therapy begun. (medscape.com)
  • A total of 117 patients who underwent curative surgery for AEG, classified as Siewert type I or II, at our institute between 2000 and 2016 were included in this study. (biomedcentral.com)
  • Patients received neoadjuvant chemoradiotherapy with carboplatin and paclitaxel for 5 weeks. (medscape.com)
  • It is a thin, weblike constriction located at the squamo-columnar mucosal junction at or near the border of the LES. (medquizzes.net)
  • As many as 59% of patients experience complications. (medscape.com)
  • Patients who show signs of GERD complications or other illness or who do not respond to therapy should be considered for further diagnostic testing. (medscape.com)
  • However, in one recent study involving 20 patients, no significant differences were noted in any of the reflux parameters measured before and after dilation. (medscape.com)
  • However, it is important to note that in both cases patients were suffering from chronic reflux before and after the surgery. (nature.com)
  • Approximately 50% of patients with gastric reflux develop esophagitis. (medscape.com)
  • The last hypothesis was based on a chance observation in one study showing that 62% of patients with rings had ingested medications known to cause pill-induced esophagitis. (medscape.com)
  • This study compared the long-term consequences of two common forms of bariatric surgery: one-anastomosis gastric bypass (OAGB) and Roux-en-Y Gastric Bypass (RYGB) in a preclinical rat model. (nature.com)
  • This study will end after the main analysis node of DFS and unblinding for analysis are achieved, or 5 years after enrollment of the last patient, whichever comes first. (centerwatch.com)
  • The study population in the primary analysis comprised 866 patients who were well balanced in terms of their co-variables. (oncotarget.com)
  • The study found no significant differences in mortality or morbidity in elderly patients. (medscape.com)
  • While that's the case for a subgroup of patients whose tumors express PD-L1 (as quantified by a combined positive score, or CPS, of 10 or above), when it came to the entire intention-to-treat population, statistical significance for OS was not met - marking a key miss in the primary endpoint. (e-cancer.fr)
  • This method was chosen to expedite the procedure and minimize bleeding in an elderly, cirrhotic patient. (hindawi.com)
  • Consequently, these authors suggest using this strategy in elderly patients. (medscape.com)
  • An increase in DCF-induced adverse events is anticipated in elderly patients, patients with organ disorders, and patients suffering from malnutrition. (biomedcentral.com)
  • Thus, the authors suggest using this strategy in elderly patients. (medscape.com)
  • Patients meeting the inclusion criteria will be 1:1 randomized into JS001-chemotherapy group and placebo-chemotherapy group. (centerwatch.com)